EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?

Andrea Portacci, Silvano Dragonieri, Giovanna Elisiana Carpagnano

The Journal of Allergy and Clinical Immunology: In Practice · 2023

DOI: 10.1016/j.jaip.2023.01.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023. Verfasst von Andrea Portacci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy. Electronic address: …. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Defining super-response to biologic treatment is a major concern in severe asthma. Although many definitions have been proposed, there is still a gap between the clinical perception of the super-response and a standardized classification. The current definition of super-response mainly relies on several clinical features, while many aspects of severe asthma inflammation and lung function are still poorly considered. Furthermore, many criteria of severe asthma super-response overlap with those of the clinical remission, leaving room for possible misclassifications. In this context, identifying the correct trajectory linking these 2 aspects of type 2-high severe asthma could help clinicians to understand which factors can predict a greater response to biologic therapies. In this paper, we review various aspects of super-response assessment, proposing some new criteria for its definition as well as new perspectives on its relationship with severe asthma clinical remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaBiological ProductsAnti-Asthmatic AgentsHumansPhenotypeBiological TherapyInflammation

Stichwörter der Autor:innen

BiologicEGPARemissionSevere asthmaSuper-responders

Substanzen

Biological ProductsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy. Electronic address: a.portacci01@gmail.com.
  • Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.

Zitieren

APA

Portacci, A., Dragonieri, S., & Carpagnano, G. E. (2023). Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2023.01.021

Vancouver

Portacci A, Dragonieri S, Carpagnano GE. Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?. The Journal of Allergy and Clinical Immunology: In Practice. 2023. doi:10.1016/j.jaip.2023.01.021

BibTeX
@article{Portacci2023,
  author = {Portacci, Andrea and Dragonieri, Silvano and Carpagnano, Giovanna Elisiana},
  title = {Super-Responders to Biologic Treatment in Type 2–High Severe Asthma: Passing Fad or a Meaningful Phenotype?},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  doi = {10.1016/j.jaip.2023.01.021}
}
Kostenlos starten →